


PHARMACEUTICAL 2022

Gain Therapeutics Inc. Rank 124 of 466









PHARMACEUTICAL 2022

Gain Therapeutics Inc. Rank 124 of 466



The relative strengths and weaknesses of Gain Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Gain Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Gain Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 213%, being 135% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	37,722
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,553
Liabilities, Non-Current	1,615
Other Assets	1,157
Other Compr. Net Income	0
Other Expenses	4.0
Other Liabilities	0
Other Net Income	-60
Other Revenues	165
Property and Equipment	106
Research and Development	7,164
Selling, General and Administrative Expense	6,827

Output Variable	Value in 1000 USD
Assets	38,985
Liabilities	4,168
Expenses	13,995
Revenues	165
Stockholders Equity	34,818
Net Income	-13,891
Comprehensive Net Income	-13,891
Economic Capital Ratio	213%

